Navigation Links
New drugs to find the right target to fight Alzheimer's disease
Date:8/2/2013

understanding of the mechanism involved has been lacking. But with this work, the EPFL researchers were able to shed some more light on it by determining how the drug compounds affect gamma secretase and its cutting activity.

In most forms of Alzheimer's, abnormally large quantities of the long amyloid peptide 42 named like that because it contains 42 amino acids are formed. The drug compounds change the location where gamma secretase cuts the APP protein, thus producing amyloid peptide 38 instead of 42, which is shorter and does not aggregate into neurotoxic plaques.

Compared to previous therapeutic efforts, this is considerable progress. In 2010, Phase III clinical trials had to be abandoned, because the compound being tested inhibited gamma-secretase's function across the board, meaning that the enzyme was also deactivated in essential cellular differentiation processes, resulting to side-effects like in gastrointestinal bleeding and skin cancer.

"Scientists have been trying to target gamma secretase to treat Alzheimer's for over a decade," explains Patrick Fraering, senior author on the study and Merck Serono Chair of Neurosciences at EPFL. "Our work suggests that next-generation molecules, by modulating rather than inhibiting the enzyme, could have few, if any, side-effects. It is tremendously encouraging."

New insights into hereditary forms of the disease

During their investigation, the scientists also identified possible causes behind some hereditary forms of Alzheimer's disease. Early-onset Alzheimer's can appear as early as thirty years of age, with a life expectancy of only a few years. In vitro experiments and numerical simulations show that in early-onset patients, mutations in the APP protein gene modify the way by which APP is cut by the gamma-secretase enzyme. This results in overproduction of amyloid peptide 42, which then aggregates into amyloid plaques.

This research illuminates much
'/>"/>

Contact: Patrick Fraering
patrick.fraering@epfl.ch
41-795-938-785
Ecole Polytechnique Fdrale de Lausanne
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Alternative target for breast cancer drugs
2. Toward broad-spectrum antiviral drugs for common cold and other infections
3. Gene variants may predict who will benefit from breast cancer prevention drugs
4. New screening technique paves the way for protein drugs from bacteria
5. Soda and illegal drugs cause similar damage to teeth
6. A new strategy required in the search for Alzheimers drugs?
7. Drugs found to both prevent and treat Alzheimers disease in mice
8. Renaissance in new drugs for rare diseases
9. Renaissance in new drugs for rare diseases: Report in worlds largest scientific socity magazine
10. How do anticancer drugs work?
11. Mapping of cancer cell fuel pumps paves the way for new drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... tropical rabbitfish which have devastated algal forests in the ... entire Mediterranean basin if their distribution continues to expand ... study, by an international team of researchers led by ... Tomas of the Mediterranean Institute for Advanced Studies in ... ., Members of the team surveyed more than 1000 ...
(Date:9/18/2014)... form of camouflage: you don,t just blend in, the ... as uncommon as you might think. Kathryn Feller, from ... the larval life stages of many marine species are ... that most creatures cannot make transparent. Feller explains that ... individual eye unit with an opaque pigment to prevent ...
(Date:9/17/2014)... Humanities has received a $260,000 grant from the Andrew ... of the Human in the Age of the Life ... of events aimed at exploring two compelling themes in ... who are exploring the boundaries of our self-definition as ... other involves the increasingly influential hypothesis that we are ...
Breaking Biology News(10 mins):Tropical fish a threat to Mediterranean Sea ecosystems 2Transparent larvae hide opaque eyes behind reflections 2Mellon Foundation awards grant for major project in the humanities and sciences 2
... are two root causes of a type of diabetes associated ... a clinical trial, may guide development of new treatments or ... Almost half of patients with CF will develop diabetes by ... their teens. In addition to the health problems caused by ...
... CORVALLIS, Ore. Diatoms, tiny marine life forms that ... biofuel production from algae truly cost-effective because they ... biomedical products and even health foods. Engineers at ... the envelope a bit. But it,s not science fiction ...
... and pregnant, your baby isn,t destined to a life of ... online in The FASEB Journal . In ... fat intake during pregnancy to a moderate level is enough ... they found that a protein called "SIRT1" rewrites a developing ...
Cached Biology News:Cystic fibrosis disrupts pancreas two ways in CF-related diabetes 2Cystic fibrosis disrupts pancreas two ways in CF-related diabetes 3Ancient diatoms could make biofuels, electronics and health food -- at the same time 2Eating well during pregnancy reduces baby's obesity risk regardless of mom's size 2
(Date:9/20/2014)... HealthTronics, Inc. , a ... products and services, has signed a distribution agreement ... Corporation for its high precision laser technology. ... invasive, mobile, surgical technology—offering more choices for healthcare ... HealthTronics will make available Clinicon’s FDA-cleared SureLase™ CO2 ...
(Date:9/19/2014)... rather than electricity, to move data would consume ... a growing concern as chips, transistor counts rise. ... circuits light emitters, modulators, and detectors ... light source for optical chips is molybdenum disulfide ... as a single, atom-thick layer. Other experimental on-chip ...
(Date:9/19/2014)... -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology ... to manufacture proteins including biosimilar therapeutics, today announced that ... Annual NewsMakers in the Biotech Industry conference in ... chief executive officer of Pfenex, will provide an overview ... Friday, September 26, 2014 at 10:00 a.m. EDT/7:00 a.m. ...
(Date:9/19/2014)... , September 19, 2014 , ... European Society for Paediatric Endocrinology (ESPE) Meeting  ... and medical research in the field of growth  , ... Darmstadt, Germany , today announced the ... for 2014. The awards were announced during a Satellite ...
Breaking Biology Technology:HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3Toward optical chips 2Toward optical chips 3Pfenex to Present at Upcoming Industry Conference on September 26 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3
... by Rice University has brought a wealth of new information ... The current issue of the American Chemical Society journal ... the Rice lab of chemist Bruce Weisman to understand how ... in this case, the light they emit at near-infrared ...
... Realty Trust, Inc. (NYSE: BMR ) today announced ... ended December 31, 2011 after the market closes on Wednesday, ... and Chief Executive Officer, Kent Griffin, President, Matt McDevitt, Executive ... host an investor conference call at 10:00 a.m. Pacific Time ...
... DURHAM, N.C., Jan. 31, 2012  Argos Therapeutics Inc., ... immune monitoring analysis of AGS-003-006, a Phase 2 ... with sunitinib in patients with advanced renal cell ... correlation between anti-tumor memory T cell responses and ...
Cached Biology Technology:Perfect nanotubes shine brightest 2BioMed Realty Trust to Report 2011 Fourth Quarter and Year End Results 2Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC) 2Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC) 3
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
... Antigen peptide transporter 2 ... (Peptide transporter PSF2) (Peptide ... (Peptide transporter involved in ... Antigen: ...
This monoclonal antibody recognizes the light chain of human Factor XII and at 100 nM inhibits 50% of Factor XII activity. It may be used in ELISA to detect human Factor XII and in coagulation assay...
Anti-LC3 Polyclonal Antibody Research Focus: cell surface antigens Storage: -20C Shipping Temperature: +4C...
Biology Products: